Tweet • Uses HER2 as a target to selectively deliver toxins to cancer cells. • Designed to overcome issues of resistance with Herceptin. PHILADELPHIA — Patients with HER2-positive breast cancer may have an alternative therapy when they develop...
Filed under: Press Releases, Research, Breast Cancer, Cancer, Media Materials, AACR, American Association for Cancer Research, Clinical Cancer Research, women, Jacek Capala, HER-2 positive, Trastuzumab, National Cancer Institute, HER2-Affitoxin, Herceptin, affibody, drug resistance, PE38, NCI